ACAT1 as a therapeutic target and its genetic relationship with Alzheimer's disease.

CONCLUSION: Although there are several lines of evidence from cell-based and animal studies that suggest that ACAT inhibition is an effective way of reducing cerebral Aβ, there is still an information gap in terms of mechanisms and concerns to cover before passing to the next level. Additionally, an area of interest that may be useful in understanding AD to subsequently propose new therapeutic approaches is pharmacogenetics; however, there is still a lot of missing information in this area. PMID: 31441726 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31441726?dopt=Abstract

Source: Current Alzheimer Research - August 22, 2019 Category: Neurology Authors: Rubio JSA, Cedillo TJ Tags: Curr Alzheimer Res Source Type: research